cjc-1295 (no dac) 5mg/vial

CJC-1295 (No DAC) 5mg/Vial Direct Research Overview

A standard cjc-1295 (no dac) 5mg/vial contains a 29-amino acid tetrasubstituted synthetic analog of growth hormone-releasing hormone (GHRH), also known as Modified GRF 1-29. Preclinical models indicate that this peptide selectively binds to the GHRH receptor (GHRHR) in anterior pituitary cells, promoting a physiological, pulsatile release of endogenous growth hormone (GH) without inducing permanent receptor downregulation or continuous non-pulsatile secretion.

Unlike extended-release constructs containing the Drug Affinity Complex (DAC), cjc-1295 (no dac) 5mg/vial exhibits a rapid elimination half-life (~30 minutes in rodent models), allowing investigators to simulate normal circadian GH signaling dynamics. Research settings utilize this compound to investigate pituitary response kinetics, downstream insulin-like growth factor 1 (IGF-1) induction, and cellular mechanisms associated with musculoskeletal repair, collagen synthesis, and metabolic regulation.

Chemical Structure and Molecular Modifications

CJC-1295 (No DAC), chemically categorized as Modified GRF 1-29, is an optimized truncation of natural human GHRH (1-44). Natural GHRH is rapidly degraded in vivo and in biological matrices by dipeptidyl peptidase IV (DPP-IV), which cleaves the peptide between the Ala2 and Asp3 positions. To prevent rapid enzymatic cleavage while retaining full receptor activation capabilities, four specific amino acid substitutions were incorporated into the structure: D-Ala at position 2, Gln at position 8, Ala at position 15, and Leu at position 27.

The resulting sequence—Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2—possesses a molecular weight of approximately 3367.9 Da. The strategic D-Ala substitution at position 2 yields substantial resistance against DPP-IV enzymatic cleavage, thereby extending the biological activity duration from minutes to an actionable experimental window, all without altering the fundamental affinity for the GHRHR.

Preclinical Mechanisms: Receptor Affinity and Endocrine Cascades

In vitro signaling assays demonstrate that CJC-1295 (No DAC) binds with nanomolar affinity to the transmembrane GHRH receptor coupled to G-alpha-s proteins. Upon ligand binding, adenylyl cyclase activation drives intracellular cyclic adenosine monophosphate (cAMP) accumulation, triggering protein kinase A (PKA) phosphorylation cascades. This signaling cascade leads to increased intracellular calcium influx and transcription of the GH1 gene within somatotroph cells.

Preclinical rodent and non-human primate studies demonstrate that administration of GHRH secretagogues induces a sharp, physiological pulse of growth hormone. This transient GH spike stimulates hepatic and local tissue production of IGF-1. Researchers investigating cell proliferation, satellite cell activation in skeletal muscle, extracellular matrix synthesis, and lipid oxidation frequently target these downstream cascades using cjc-1295 (no dac) 5mg/vial to monitor systemic and localized tissue repair biomarkers.

Comparative Analysis: GHRH Analogs and Secretagogues

Understanding the comparative dynamics of growth hormone secretagogues is critical when designing target-specific in vitro or animal models. While CJC-1295 (No DAC) acts directly on the pituitary GHRH receptor with an intermediate half-life, other compounds within the secretagogue class exhibit distinct structural and pharmacokinetic profiles.

For instance, CJC-1295 with DAC includes a maleimidopropionic acid linker that covalently binds to circulating serum albumin, extending its biological half-life to several days and producing sustained, non-pulsatile GH release. Conversely, native-sequence Sermorelin retains the unmodified GRF 1-29 sequence, rendering it susceptible to rapid DPP-IV breakdown. When evaluating dual-pathway secretagogue synergy, researchers frequently co-administer GHRH analogs with ghrelin receptor agonists like Ipamorelin or GHRP-6, which act via the growth hormone secretagogue receptor (GHS-R1a) to produce additive GH release. Exploration of these combined pathways is detailed further in the PX1 Research Library.

PX1 Research Quality Verification and Sourcing Standards

To prevent experimental artifacting caused by peptide degradation products, TFA residue, or microbial contaminants, PX1 Research maintains stringent analytical verification protocols for every batch of cjc-1295 (no dac) 5mg/vial. All products are synthesized in US-based, GMP-compliant facilities and tested by an independent ISO 17025 accredited laboratory prior to release.

Key evaluation metrics for every production lot include:

• Purity Determination: Verified via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to consistently ensure ≥98% purity, minimizing truncated peptide fragments.

• Mass Verification: Electrospray Ionization Mass Spectrometry (ESI-MS) confirms exact molecular weight (3367.9 Da ± 1 Da) and sequence fidelity.

• Endotoxin Control: Kinetic Chromogenic LAL testing verifies endotoxin levels below 0.1 EU/mg, preventing inflammatory interference in cell cultures or animal research.

• Lyophilization Quality: Produced as a stable, white freeze-dried cake under vacuum, ensuring minimal residual moisture content.

• Lot Traceability & Same-Day Dispatch: Orders ship same-day (Monday through Friday) from CA or AZ fulfillment hubs, complete with public, lot-matched Certificates of Analysis.

Laboratory Reconstitution and Handling Procedures

Reconstitution of a cjc-1295 (no dac) 5mg/vial must be performed under aseptic conditions within a laminar flow hood to maintain sterility. For multi-dose laboratory sampling or extended trial protocols, bacteriostatic water containing 0.9% benzyl alcohol is recommended as the diluent to inhibit microbial growth. Alternatively, sterile 0.9% sodium chloride or phosphate-buffered saline (PBS) may be used for immediate single-use in vitro assays.

When introducing solvent into the lyophilized vial, direct the stream against the inner glass wall rather than directly onto the peptide cake. Gently swirl or roll the vial between hands until the lyophilized powder is completely dissolved. Avoid vigorous agitation or vortexing, as mechanical shear stress can disrupt the secondary structure and cause peptide aggregation. Reconstitution calculations (e.g., adding 2.5 mL solvent to a 5mg vial yields a concentration of 2.0 mg/mL) should be documented before starting protocol runs.

Storage Parameters and Degradation Prevention

Proper temperature control is vital to preserve the peptide backbone and prevent peptide oxidation or deamidation over time. Lyophilized CJC-1295 (No DAC) 5mg vials should be stored at -20°C in a manual defrost freezer for long-term storage (up to 24 months). Store vials protected from light exposure to prevent photo-oxidation of vulnerable amino acid residues such as tyrosine and tryptophan.

Once reconstituted with bacteriostatic water, the liquid solution must be refrigerated at 2°C to 8°C and utilized within 21 to 30 days. Reconstituted solutions without preservative (e.g., reconstituted in pure sterile water) should be used immediately. Repeated freeze-thaw cycles of liquid aliquots must be strictly avoided; researchers requiring frozen aliquots should divide the reconstituted solution into single-use sterile microcentrifuge tubes immediately after dissolving and store them at -80°C.

In Vitro and Animal Model Protocol Considerations

In preclinical model design, CJC-1295 (No DAC) is typically deployed to evaluate the physiological kinetics of pulsatile GHRH stimulation. Because it lacks the DAC moiety, its rapidly clearing profile allows researchers to administer finite pulse inputs in rodent or cell culture models, accurately measuring acute GH spikes without persistent background stimulation.

Researchers evaluating tissue regeneration, protein synthesis rates, or bone density markers frequently analyze biological samples (such as serum or tissue lysates) at designated post-exposure intervals (e.g., 15, 30, 60, and 120 minutes). Cross-referencing these kinetic curves against baseline GHRH inputs allows precise quantification of receptor sensitivity and downstream signaling efficiency. Explore our complete catalog of growth hormone secretagogues to review parallel assay designs.

Bulk Procurement and Institutional Wholesale Supply

PX1 Research accommodates institutional laboratories, academic research departments, and contract research organizations (CROs) requiring large-volume supplies of high-purity peptides. Institutional purchasing programs offer scalable batch sizes, dedicated account management, and standardized lot reservation to guarantee batch consistency across longitudinal multi-year studies.

Principal investigators and laboratory directors seeking bulk procurement options for all research peptides can request custom synthesis quotas or establish institutional accounts directly via our wholesale laboratory portal.